Strategy Inc. vs Sanofi SA — how do they compare? Strategy Inc. trades at $101.84 (market cap $35.47B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 3× Strategy Inc.'s market cap, and Sanofi SA pays a 5.5% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| MSTR | SNY | |
|---|---|---|
Market Cap | $35.47B | $104.83B |
Sector | Technology | Health |
52-Week High | $426.40 | $52.34 |
52-Week Low | $82.31 | $41.33 |
Enterprise Value | $50.50B | $121.32B |
Dividend Yield | — | 5.5% |
Trailing returns across standard periods
Latest headlines on both assets
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →